Status:
UNKNOWN
Juvenile Autoimmune Necrotizing Myopathies
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Immune-Mediated Necrotizing Myopathy
Eligibility:
All Genders
Brief Summary
Autoimmune necrotizing myopathies (AINM) in adult patients are characterized by severity of muscle damage, presence of necrosis with little inflammation on muscle biopsy and anti-HMGCR or anti-SRP aut...
Eligibility Criteria
Inclusion
- AINM histologically proved by predominant muscle fibers necrosis lesions associated with minimal or absent inflammatory lesions
- Either anti-SRP or anti-HMGCR antibodies positivity
- Disease onset before age 18
Exclusion
- Seronegative necrotizing myopathies
- Forms compatible with another type of myositis (e.g. dermatomyositis)
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04295785
Start Date
March 1 2020
End Date
November 1 2020
Last Update
March 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital d'enfants CHRU Nancy
Vandœuvre-lès-Nancy, France, 54 500